Verona Pharma is not a company subject to regulation under the City Code on Takeovers and Mergers (the “UK Takeover Code”), therefore no dealing disclosures are required to be made under Rule 8 of the ...

AFFIRM-1 trial did not meet primary endpoint or secondary endpointsCompany to conduct strategic review of portfolio and business ...

Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression ...

Atezolizumab shows no significant benefit over BCG alone in treating high-risk non-muscle invasive bladder cancer, according to the ALBAN trial results.

AFFIRM-1 trial did not meet primary endpoint or secondary endpoints Company to conduct strategic review of portfolio and business operations BURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Neupho ...

Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout anticipated in early Q4 2025 Cash runway extended through fisca ...

The decrease of $0.4 million was primarily due to the timing of clinical and consulting related spend ... In addition, Neuphoria has a strategic partnership with Merck & Co., Inc. (known as MSD ...

MSD and Eisai presented the data at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The ...

12-year-old trains young pit bull with perfect control and timing. Supreme Court rejects appeal from Ghislaine Maxwell, imprisoned former girlfriend of Jeffrey Epstein Michelle Pfeiffer Recalls Bloody ...

Dura-Belt’s Jim Hammond shares his expert insights about designing, manufacturing and maintaining thermoplastic elastic belts ...

Introducing this year's exceptional Black British Business Awards2025 (BBBAwards) winners; representing the very best of entrepreneurs, corporate leaders and innovators from global corporations such ...